India's hospital sector to sustain 11-12% growth, driven by insurance penetration and medical tourism: CareEdge

India's hospital sector is set for strong growth. Rising insurance and medical tourism are key drivers. Affordable treatment attracts global patients. Corporate hospitals show steady revenue gains. Bed capacity additions support future expansion. Financial health is improving with stable margins and reduced debt. This positive trend is expected to continue.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FW40j3y
via IFTTT

Read More

Ministry in talks with states to give some drug cos more time for good manufacturing practices compliance

The Union Health Ministry is in talks with states about extending the deadline for pharmaceutical companies to meet new manufacturing quality rules. A six-month extension may be granted on a case-by-case basis. This move aims to prevent potential medicine shortages and job losses. Many smaller drug units might otherwise face closure.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/b12VxAq
via IFTTT

Read More

Nimesulide banned: Govt puts a stop to manufacture, sale of all oral formulations containing the popular painkiller above 100 mg

Nimesulide sale banned: The move follows recommendation by India’s top research body- Indian Council of Medical Research (ICMR). In it’s earlier report to the drug regulatory body it had ecommended a total ban on all formulations of ninrsulide above 100 mg strength.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sQ4ek7J
via IFTTT

Read More

Run, rave, repeat! Wellness turns social for Gen Z

Gen Z embraces wellness through social activities like pickleball and dance workouts. Brands are set to sponsor these events in 2026. Physical wellness is now a social identity. Gen Z is also choosing low and no-alcohol drinks. This zero-proof trend will continue. Non-alcoholic cocktails are emerging for social settings.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xgVRHDs
via IFTTT

Read More

Doctors warn against antibiotic misuse as resistance threat grows

Leading doctors are warning the public about the dangers of antibiotic resistance. They stress that antibiotics must only be used under a doctor's prescription. Careless use is making infections harder to treat. India is a major consumer of these medicines. Many hospital infections now resist common antibiotics. This misuse threatens future healthcare. Patients, doctors, and the industry must act responsibly.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/adJD7gC
via IFTTT

Read More

Experts recommend 'micro-hospitals' as India's new shield against rising non-communicable diseases

India faces a growing epidemic of non-communicable diseases. Experts propose a solution: micro-hospitals. These facilities will offer specialist-led coordinated care and reduce wait times. This model aims to bridge the gap between primary clinics and large hospitals. Micro-hospitals will provide diagnostics and interventions closer to communities. This approach promises better patient outcomes and restored trust in healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CdLVJDW
via IFTTT

Read More

Odisha, Delhi join AB-PMJAY, robust growth in digital healthcare delivery in 2025; AI next frontier

In 2025, India expanded Ayushman Bharat to Odisha and Delhi, boosting digital health with eSanjeevani's 43.2 crore tele-consultations. The Ayushman Bharat Digital Mission saw 84.35 crore health accounts created. Progress in TB elimination was globally recognized, with a 21% incidence decline and AI integration strengthening public health delivery.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bxn7BqS
via IFTTT

Read More

Abhayrab rabies vaccine: IIL says counterfeit batch no longer available

Indian Immunologicals Limited clarifies a packaging anomaly in one batch of its anti-rabies vaccine, Abhayrab. The company states that counterfeit batches are no longer available. This follows an alert from Australian health authorities regarding potentially unprotected travelers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9V4syBc
via IFTTT

Read More

US may impose duties on Indian capsule makers

The US Department of Commerce has made a significant finding. Indian producers and exporters of hard empty capsules have received countervailable subsidies. This determination could lead to new duties on these exports. The investigation covered a recent one-year period.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T3Ydri0
via IFTTT

Read More

Obesity drugs shed niche tag, set to gain more weight in India pharma

India's obesity drug market is experiencing rapid growth, driven by rising lifestyle diseases and the launch of blockbuster therapies. The impending entry of low-cost generics is set to further accelerate this expansion, making treatments more accessible to a wider population beyond urban elites.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4v5Ooz6
via IFTTT

Read More

Air pollution India's biggest health crisis since Covid, warn doctors

Speaking to PTI, multiple senior doctors practising in the UK asserted that a vast, hidden burden of undiagnosed airway disease is "building beneath the surface" and its incoming wave will exact a heavy, lasting toll on Indian citizens and its healthcare system.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YwLWXHv
via IFTTT

Read More

Experts warn of risks from govt price floor on key pharma inputs

The government has proposed to impose MIP on Penicillin-G (Pen-G), with possible extension to 6-aminopenicillanic acid (6-APA) and amoxicillin. Penicillin-G is not a standalone product. It is the upstream 'mother molecule' for a wide range of essential antibiotics, feeding into intermediates such as 6-APA, GCLE and 7-ADCA, and into high-volume formulations including amoxicillin, ampicillin, multiple cephalosporins and widely used combinations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iLpRMt5
via IFTTT

Read More

Sun Pharma arm recalls over 17,000 units of antifungal shampoo in US: USFDA

Taro Pharmaceutical Industries, a Sun Pharma unit, is recalling 17,664 units of Ciclopirox Shampoo in the US. The antifungal medication is being recalled due to failed impurity specifications. This Class II nationwide recall was initiated on December 9. The USFDA stated the recall is for temporary or medically reversible health consequences. Sun Pharma completed its merger with Taro last year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/No1yCYD
via IFTTT

Read More

Sequent-Viyash may soon have zero debt: Viyash founder and combined co's CEO-designate Hari Babu Bodepudi to inject ₹400 crore

Hari Babu Bodepudi is making a significant capital infusion into the newly merged Sequent Scientific and Viyash Life Sciences. This strategic investment will effectively reduce the combined company's net debt to nearly zero. Under Carlyle's leadership, the newly formed entity is poised to surpass a market capitalization of $1 billion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/S9bJvfq
via IFTTT

Read More

Health(y) Inc: Top private hospitals see spurt in per-bed revenue

India's leading private hospitals are experiencing a significant revenue surge per bed, driven by advanced high-tech treatments and increased insurance coverage. This trend, reflected in 2024-25 data, shows a 23% rise in average daily revenue per bed, indicating a broader shift towards specialized and expensive medical procedures becoming more accessible to patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BUgFR4v
via IFTTT

Read More

Intense Lilly, Novo rivalry throws India weight-loss drug race wide open

Eli Lilly and Novo Nordisk are in a race to dominate India's booming obesity drug market. They are using aggressive marketing, doctor outreach and partnerships. Lilly's Mounjaro launched early and is leading sales. Novo Nordisk is cutting prices and launching Ozempic. Generic versions are expected next year, intensifying the competition in this price-sensitive market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dr5jXoy
via IFTTT

Read More

Bristol Myers lines up many launches for India with 'AI' speed

Bristol Myers Squibb sees India as a major growth driver. The company is investing heavily in AI to speed up drug launches and improve doctor engagement. New medicines for heart conditions and cancer are coming to India. This strategic move aims to boost sales and prepare for patent expirations. India is becoming a hub for AI innovation for the company.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/t7Dn5Xl
via IFTTT

Read More

Customs duty waiver likely for SEZ-made drugs sold locally

India may soon waive customs duty on medicines produced in special economic zones for local sale. This move aims to reduce costs and increase the availability of essential drugs and vaccines within the country. The proposal could be part of the upcoming Union budget.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r0qA4Gm
via IFTTT

Read More

Bharat Biotech, Biofabri in tech transfer deal for TB vaccine

MTBVAC, the TB vaccine, has undergone Phase I and II clinical trials in India. The vaccine has demonstrated safety and immunogenicity. Based on the initial results, Bharat Biotech is preparing for a pivotal Phase III vaccine efficacy study. It will start recruiting participants in the first quarter of 2026.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eK3d1uL
via IFTTT

Read More

Be patient... prices of your medicines may come down soon

Indian medicines may become more affordable as China's active pharmaceutical ingredient (API) prices have dropped significantly, by 35-40%. This reduction in manufacturing costs for generic drug makers is expected to translate into lower medicine prices for consumers. Experts anticipate further price declines in the coming months.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GaHfzd3
via IFTTT

Read More

Park Medi World to acquire KP Institute of Medical Sciences for ₹245 crore

Park Medi World is acquiring KP Institute of Medical Sciences for Rs 245 crore. This all-cash deal will add 360 beds to Park Medi World's network. The acquisition aims to strengthen the hospital chain's presence in North India. Integration is expected to improve clinical programs and efficiency. The company anticipates significant value addition soon after the transaction is complete.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oVGSnRO
via IFTTT

Read More

Emcure Pharma launches weight loss drug Poviztra in India

Emcure Pharmaceuticals has launched Poviztra, a semaglutide injection for weight loss, becoming the first Indian company to exclusively distribute Novo Nordisk's medication. Available in a once-weekly pen device, Poviztra is indicated for chronic weight management in adults with obesity and at least one weight-related comorbidity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VHFAsre
via IFTTT

Read More

Motilal Oswal Alternates invests $72 million in Sensa Core Medical

Motilal Oswal Alternates has invested $72 million in Sensa Core, a Hyderabad-based medical devices company. Sensa Core, a leader in electrolyte analyzers, exports to over 78 countries and manufactures glucometers and hemoglobin meters. This investment supports India's growing medical device sector and aims to improve healthcare access through local manufacturing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8nfevty
via IFTTT

Read More

Granules unit gets USFDA nod for generic drug

Granules India has secured tentative approval from the USFDA for its generic ADHD medication. This approval is for Amphetamine extended-release orally disintegrating tablets. The drug is a generic version of Adzenys XR-ODT. It will be manufactured at Granules' US facility. The medication treats Attention Deficit Hyperactivity Disorder. This move strengthens Granules' presence in the Central Nervous System therapeutic area.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2xWXZ1P
via IFTTT

Read More

Young doctors free to go abroad, but can no longer say facilities lacking in India: JP Nadda

Asserting that the country's medical education landscape has transformed under Prime Minister Narendra Modi, the Union health minister said the number of All India Institute of Medical Sciences (AIIMS) in the country has gone up to 23.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/znLhWuT
via IFTTT

Read More

Fortis to acquire Bengaluru’s People Tree Hospitals for Rs 430 crore

Fortis Healthcare Limited is set to acquire TMI Healthcare Private Limited, which operates People Tree Hospitals in Bengaluru, for Rs 430 crore. The deal includes the hospital, its infrastructure, land, and an adjacent parcel. This strategic acquisition aims to expand Fortis's presence in the region, leveraging People Tree's established multispecialty services.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gRlxm14
via IFTTT

Read More

Centre draws a price line to curb cheap pharma imports

India has set a minimum import price for essential drug ingredients. This move aims to protect domestic manufacturers from aggressive pricing by Chinese companies. The restrictions will be in place until November 2026. Some experts worry this could increase medicine costs for patients. The government launched a scheme to boost local production and reduce reliance on China.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nxuQKYh
via IFTTT

Read More

Cipla, Pfizer ink partnership for exclusive marketing of four brands in India

Pfizer India and Cipla Limited have announced a strategic partnership where Cipla will exclusively market and distribute four of Pfizer's key brands in India. This collaboration aims to leverage Cipla's extensive distribution network to enhance patient access to essential medicines like Corex Dx, Dolonex, Neksium, and Dalacin C across the country.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/S3hPJzi
via IFTTT

Read More

Centre weighs new law to regulate medical research

In an ambitious step forward, India is drafting a new law to enhance medical research practices. This forthcoming Bill seeks to establish robust ethical benchmarks while prioritizing safety and quality. At the behest of the Prime Minister's Office, the Indian Council of Medical Research is spearheading this initiative.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/f01svbQ
via IFTTT

Read More

USFDA issues Form 483 with 5 observations to Aurobindo Pharma's Andhra unit

Aurobindo Pharma said the USFDA issued a Form 483 with five procedural observations after inspecting Unit-IV of its subsidiary APL Healthcare in Andhra Pradesh from December 8–17, 2025. The company said it will respond within stipulated timelines and remains committed to quality standards.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xvuwkpa
via IFTTT

Read More

FDA cancels licences of 13 medical stores, suspends 32 over sale of intoxicant tablets in Nanded

Nanded's medical stores face strict action. The Maharashtra Food and Drug Administration has cancelled licenses of thirteen stores and suspended thirty-two. This action follows the alleged sale of intoxicant tablets without a doctor's prescription. The FDA investigated forty-eight stores, finding violations of the Drugs and Cosmetics Act.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bs9RBZM
via IFTTT

Read More

US FDA issues 'Official Action Indicated' status to Sun Pharma’s Baska facility after inspection

Sun Pharmaceutical Industries Ltd announced that its Baska manufacturing facility has been classified as Official Action Indicated (OAI) by the US FDA following a recent inspection. Despite this classification, the company confirmed that supplies to the US market from the plant will continue uninterrupted. Sun Pharma stated it will collaborate with the regulator to ensure full compliance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7OhGSwU
via IFTTT

Read More

India's pharma exports cross $30 billion: Rajesh Agrawal

India's pharmaceutical exports have surpassed $30 billion in FY25. The nation stands as a trusted global supplier of quality and affordable medicines. India is the third largest producer by volume and 14th by value. Medicines reach over 200 markets. The domestic market is projected to reach $130 billion by 2030.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jKa36cP
via IFTTT

Read More

Oral cancer preventable if detected early, says Kidwai Institute cancer expert

Most oral cancer patients in India seek out medical assistance at stage three or four largely due to ignorance and delayed diagnosis. If dentists identify and refer cases at an early stage, patients can receive timely treatment, which will improve the chances of their survival, Dr Nadimul Hodasaid.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eyjBu7I
via IFTTT

Read More

Novartis bets big on India, builds its largest global R&D hub outside Switzerland

Novartis is significantly expanding its biomedical research and drug development operations in India, positioning it as a key global hub outside Switzerland. With over 9,000 employees, Indian teams now contribute to nearly every Novartis molecule in late-stage development, driving high-value, science- and data-led innovation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lYqgXyR
via IFTTT

Read More

Reliance eyes Jio-style disruption in genomics with sub-Rs 1,000 tests

The energy-to-retail conglomerate is leveraging Strand Life Sciences for its entry into the emerging areas of specialised healthcare diagnostics and genomic sciences. Reliance had acquired the Bengaluru-based company for ₹393 crore in 2021.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LZk9Cp5
via IFTTT

Read More

Supriya Lifescience targets Rs 1,600-cr revenue in three years on capacity expansion

Supriya Lifescience plans to reach Rs 1,600 crore revenue in three years. New facilities in Lote MIDC and Ambernath will drive this growth. The company focuses on niche, complex APIs, moving away from mass-volume products. New product launches and contract manufacturing tie-ups are also planned. Supriya Lifescience is debt-free, funding expansion through internal accruals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QerLS2v
via IFTTT

Read More

IHH Healthcare to expand India capacity to 7,000 beds by 2028

IHH Healthcare is set to significantly boost its Indian capacity to approximately 7,000 beds by 2028, following a stake increase in Fortis Healthcare. This expansion, aiming for an additional 2,000 beds, will leverage synergies between Fortis and Gleneagles Healthcare India to enhance patient care and operational efficiency across its 35 hospitals nationwide.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TwUqnoX
via IFTTT

Read More

Why are so many Indian hospitals rushing to the market?

India's healthcare sector is poised for a significant IPO boom in 2026, with hospitals and allied services expected to raise Rs 20,000 crore. This surge is driven by improving financials, strong demand due to underpenetration, and private equity backing. Specialty care and medical tourism also fuel this growth, making public markets a strategic avenue for expansion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4u2RrEF
via IFTTT

Read More

Trial by fire: Over 60% of pharma SMEs may be forced to shut shop

India is estimated to have about 12,000 drug manufacturing units. The units that risk being shut down account for about Rs 75,000 crore of India's Rs 2.5 lakh crore domestic drug market, the executives said. This may result in shortages of antibiotics, anti-hypertensives, anti-inflammatory medicines, analgesic, anti-cough and cold tablets, diabetes drugs and general medicines, among others, said a pharma industry expert, speaking on the condition of anonymity. "The shortages of medicines will be seen across the country. Many of these units also cater to government supplies along with supplies to tier-II and tier-III cities and exports."

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZywaBmQ
via IFTTT

Read More

Lords Mark Industries Ltd.–Renalyx approved to manufacture Class C AI-based haemodialysis machines; earns global CE marking

Lords Mark Industries Ltd. has achieved a significant feat by securing a CDSCO license to produce Class C AI-based smart haemodialysis machines, bolstering India's healthcare tech self-reliance. This innovation, also CE-marked, signifies a global leap in advanced renal care, positioning India as a leader in sophisticated medical equipment manufacturing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rm47NML
via IFTTT

Read More

No scientific link found between COVID-19 vaccination, sudden deaths in young adults: AIIMS study

Sudden death in young adults is a significant concern requiring targeted public health strategies, the study said, underlying coronary artery disease remains the leading cause and that respiratory and unexplained deaths warrant further investigation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4EZCQJu
via IFTTT

Read More

Delhi to run 11 hospitals under PPP model, add over 10,000 beds

Delhi government is moving forward with a plan to operate eleven government hospitals through a public-private partnership. Most of these hospitals are currently under construction.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/D9YRGf1
via IFTTT

Read More

Himachal drug cos under stop orders found operational

Himachal Pradesh's drug regulation bodies came across a concerning trend: numerous pharmaceutical companies were found to be operating illicitly, despite official directives to cease manufacturing after failing quality evaluations. Inspections indicated these firms may not have stopped production as mandated.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yanSpsX
via IFTTT

Read More

Novo Nordisk bets on cheaper Ozempic to dominate India’s booming weight-loss market

Novo Nordisk has launched Ozempic in India at a competitive price, aiming to capture a significant share of the growing weight-loss market. Leveraging its established dominance in diabetes care and insulin leadership, the company seeks to accelerate adoption of its GLP-1 therapy, positioning it against rivals like Eli Lilly.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gNUOtVo
via IFTTT

Read More

Novo Nordisk brings blockbuster weight-loss drug Ozempic to India

Danish drugmaker Novo Nordisk has launched its popular diabetes drug Ozempic in India. The drug is now available at a starting price of Rs 2,200. India has a significant number of people with type 2 diabetes and rising obesity. This makes it a key market for global drugmakers. Ozempic is a weekly injectable treatment for type 2 diabetes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tvbRzVm
via IFTTT

Read More

Delhi HC allows Dr. Reddy’s to export weight-loss drug semaglutide, calls Novo Nordisk’s case ‘weak’

The Delhi High Court declined to stay a single-judge order allowing Dr. Reddy's to export its semaglutide, observing Novo Nordisk's appeal presented a weak case. This decision permits Dr. Reddy's to supply the drug to countries without Novo Nordisk's patent protection, while the broader legal dispute over intellectual property continues.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zfiOv8p
via IFTTT

Read More

Glenmark to launch generic medication in US

Glenmark Pharmaceuticals will launch a new generic medication in the United States this month. This drug treats anaemia. It also prevents side effects from certain medications. Glenmark Pharmaceuticals Inc. USA will distribute the Leucovorin Calcium for Injection USP.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6NU7nBq
via IFTTT

Read More

Cipla launches drug for obesity, diabetes

Cipla has launched Yurpeak, a new injectable medication for obesity and type-2 diabetes. This one-weekly therapy, tirzepatide, is now available in India. Yurpeak aims to address two significant health challenges in the country. Cipla is collaborating with Eli Lilly for this innovative treatment. The drug will be offered in multiple strengths.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GTy1s35
via IFTTT

Read More

Zydus Lifesciences introduces biosimilar to protect bone health in cancer patients

Zydus Lifesciences has launched Zyrifa, a Denosumab biosimilar, for treating osteoporosis and preventing skeletal complications in cancer patients. Priced at Rs 12,495, the drug aims to improve access and affordability for patients with bone metastases from various cancers. This initiative supports patients in retaining mobility during their cancer treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qgTzBUI
via IFTTT

Read More

Delhi HC allows Sun Pharma to manufacture, export its own weight loss drug

The Delhi High Court has allowed Sun Pharma to manufacture and export its version of semaglutide, the diabetes and anti-obesity drug made by Novo Nordisk as Wegovy. However, the court barred Sun from selling the drug in India until March 2026, when Novo Nordisk’s secondary patent expires. Sun must file an affidavit and export account details, with the case next heard on February 19.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/G2UScZI
via IFTTT

Read More

'Safeguards' slowing down access to breakthrough drugs in India

New drugs are not reaching low and middle income countries. A study shows many medicines take years to become accessible globally. India's regulatory system needs to mature for quicker access to breakthrough therapies. Stronger intellectual property protection and global standardisation are key. This will help reduce delays in drug availability for patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zm562ih
via IFTTT

Read More

Telangana’s loss is Andhra’s gain as pharma companies expand in Kurnool

Sigachi Industries and Virupaksha Organics are relocating expansion projects to Andhra Pradesh. They will establish new manufacturing units in Kurnool district's Orvakal Industrial Park. This move follows Telangana's decision to abandon its Pharma City plan.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HoI8ZSY
via IFTTT

Read More

Respiratory drug sales peak in November amid worsening AQI

India's air quality decline is boosting medicines for breathing problems. The respiratory drug market grew 8% last month, a rise from previous years. This trend highlights a strong link between pollution and illness. States like Uttar Pradesh and Uttarakhand saw significant sales increases for asthma and COPD treatments. Antihistamine use also climbed.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xI32Cmw
via IFTTT

Read More

Dr Reddy’s inks licensing deal to sell Immutep’s cancer drug

Dr. Reddy's Laboratories has secured an exclusive licensing agreement with Immutep to manufacture, develop, and distribute the Australian company's cancer therapy, eftilagimod alfa. This significant deal, valued at up to $350 million, grants Dr. Reddy's distribution rights across most global markets, excluding North America, Europe, Japan, and Greater China.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KnlBJLy
via IFTTT

Read More

ET Exclusive | Biologics merger with Biocon most value-accretive option: Kiran Mazumdar Shaw

Biocon is fully integrating Biocon Biologics, valuing its biosimilar business at $5.5 billion. This move removes debt concerns and improves financial health. The combined entity will leverage synergies across manufacturing, R&D, and commercial operations. This integration aims to accelerate launches in major markets and unlock significant growth opportunities for the unified global player.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rvdhy2q
via IFTTT

Read More

Biocon to make Biocon Biologics a wholly owned subsidiary

Biocon is set to fully integrate its biosimilar arm, Biocon Biologics. This move will make Biocon Biologics a wholly owned subsidiary. Biocon will acquire remaining stakes through a share swap. The deal values Biocon Biologics at $5.5 billion. This integration aims to streamline operations and enhance strategic focus.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CZqtSm5
via IFTTT

Read More

Abbott asks stockists to buy only from authorised suppliers

Spurious medicines were seized in Puducherry, prompting drug maker Abbott Healthcare to warn stockists. They must buy only from authorized suppliers. The government alerted the Drug Controller General of India about the circulation of fake drugs. The All India Organisation of Chemists and Druggists issued an advisory for safe business practices. This is a serious trade alert.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/npGh9NW
via IFTTT

Read More

Lupin gets USFDA nod for multiple sclerosis drug

Drug maker Lupin has secured approval from the US health regulator for its generic multiple sclerosis treatment. The company received tentative approval from the USFDA for Siponimod Tablets. This new product will be manufactured at Lupin's Pithampur facility. Siponimod Tablets are bioequivalent to Mayzent tablets and treat relapsing forms of multiple sclerosis in adults.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fWTzvcA
via IFTTT

Read More

AI and technology tackling India’s growing stroke crisis: Early detection and prevention take centre stage

India faces a mounting crisis with a 51% rise in stroke cases over the last 30 years, recording 1.25 million new strokes in 2021 alone. Yet only a quarter of Indians have access to stroke-ready hospitals. Doctors at the Medtronic X EconomicTimes.com “Stroke Pe Rok” webinar agreed that creating awareness, improving primary care screening, and leveraging emerging technology must become urgent priorities to save lives and reduce stroke burden in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3K5o8sy
via IFTTT

Read More

GSK India plans big 'reinvention', MD Bhushan Akshikar reveals

GlaxoSmithKline Pharmaceuticals is planning a major comeback in India. The company aims to double its revenue to ₹8,000 crore within the next 4-5 years. This growth will be driven by a strategic shift towards specialty drugs in oncology and liver diseases. Adult vaccination is also a key focus area.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nvbyTH2
via IFTTT

Read More

NABL accreditation sets the stage for Lords Mark Microbiotech’s growth and preventive health push

Lords Mark Microbiotech, a Lords Mark Industries subsidiary, has earned NABL accreditation. This validates their diagnostic services. The company plans to open 200 labs and 2,000 collection centers nationwide in two years. They aim to become a top pathology player. An Organ Health Score offers personalized health insights. This expansion focuses on preventive healthcare.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1HWOlN9
via IFTTT

Read More

Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment

The joint studies showed some improvement in a few biological measures of the disease, but most of the changes were small and not enough to make a difference in delaying cognitive decline.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qikjFVD
via IFTTT

Read More

Sun Pharma unit to invest Rs 3,000 cr on new plant in Madhya Pradesh

Sun Pharmaceutical Industries' subsidiary, Sun Pharma Laboratories Ltd, has approved a Rs 3,000 crore investment for a new greenfield formulations manufacturing facility in Madhya Pradesh. This significant expansion by the Mumbai-based drug major aims to bolster its production capabilities. The announcement comes as Sun Pharma's shares saw a slight increase on Wednesday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/F76BokX
via IFTTT

Read More

India weight-loss market reset? In setback for Novo Nordisk, Dr Reddy's Lab allowed to make semaglutide

The order follows the court’s view that Novo Nordisk’s patent appears prima facie invalid -- a finding that could reshape competitive dynamics in a market valued at around Rs 850 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZcG9JDB
via IFTTT

Read More

Novo Nordisk India partners with Healthify to launch AI-enabled patient support programme

Novo Nordisk India and Healthify have launched a new programme. It offers AI-assisted lifestyle guidance for people with obesity. This partnership aims to improve patient experience and treatment results. An AI assistant will help users track nutrition throughout their treatment journey.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NrLORbi
via IFTTT

Read More

HC lets Dr Reddy's Laboratories export Semaglutide, blocks India sales till March '26

The Delhi High Court has permitted Dr Reddy's Laboratories to produce and export its version of the diabetes and anti-obesity drug semaglutide. This decision comes amidst a patent infringement case filed by Novo Nordisk. Dr Reddy's is restricted from selling the drug within India until March 2026. The court acknowledged a valid challenge to Novo Nordisk's patent for semaglutide.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/upk0RgU
via IFTTT

Read More

Jubilant Pharmova names Daniel J O'Connor as CEO of proprietary drugs biz

Jubilant Pharmova has appointed Daniel J O'Connor as the CEO of its novel drugs business. O'Connor brings over 30 years of leadership experience in biotechnology and oncology. His expertise includes creating value around differentiated, IP-rich platforms. Previously, he was CEO of Ambrx Biopharma, where his leadership led to a significant increase in company valuation and its successful acquisition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9ITnu4N
via IFTTT

Read More

Cough syrup row puts regulators on overdrive to test pharma products

Indian drug companies are significantly increasing product testing. This surge follows strict government rules and joint inspections by regulators. The focus is on ensuring quality after recent contamination issues. Testing volumes have jumped dramatically. Companies are investing in specialized equipment to detect toxic substances. This heightened vigilance aims to safeguard public health and maintain the integrity of India's pharmaceutical industry.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/p2w1POC
via IFTTT

Read More

Wockhardt gets NDA status for novel antibiotic Zaynich

Wockhardt, an emerging powerhouse in the Indian pharmaceutical arena, has just scored a game-changing triumph! The US health regulator has given the green light to its New Drug Application for Zaynich, a cutting-edge antibiotic. This pivotal moment signifies the first occurrence of an Indian firm securing FDA acceptance for a New Chemical Entity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KYnqwyE
via IFTTT

Read More

Lupin gets USFDA nod for biosimilar drug

Lupin gets USFDA approval for Armlupeg, a biosimilar to Neulasta, to treat neutropenia in cancer patients. The drug will be manufactured at Lupin’s Pune facility. Armlupeg aims to reduce infection risk from chemotherapy, and Lupin plans to expand its US biosimilar portfolio. The US market for Pegfilgrastim is worth over $1.29 billion annually.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Tj2Ivca
via IFTTT

Read More

Sun Pharma brings global psoriasis drug ILUMYA to Indian market

Sun Pharmaceutical Industries has launched its innovative biologic drug, ILUMYA, in India for moderate-to-severe plaque psoriasis. This novel treatment, Tildrakizumab, has a proven track record globally for providing significant and sustained skin clearance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/e5Ki80u
via IFTTT

Read More

Lupin Pharma, TPG Capital & EQT in talks to acquire Lalvani family-owned Vitabiotics

Indian drugmaker Lupin and private equity firms are exploring the acquisition of UK's Vitabiotics. The deal is valued at approximately one billion pounds. Several Indian companies had previously considered the acquisition but stepped back due to valuation concerns. Vitabiotics' Indian arm, Meyer Vitabiotics, contributes significantly to its annual sales. The nutraceutical market in India is experiencing rapid growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sNV1AuZ
via IFTTT

Read More

Torrent Pharma fined Rs 41 crore over alleged wrong GST refund

Torrent Pharmaceuticals has been fined Rs 41 crores by the Central GST Ahmedabad South Commissionerate. The company faces allegations of wrongful refund claims on export of goods. Torrent Pharmaceuticals plans to appeal the order.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6HOgYLl
via IFTTT

Read More

Apollo Pharmacy targets 10 crore customer base in 5 years, to open 2 new stores per day: CEO

Apollo Pharmacy plans an aggressive expansion, aiming to open two new stores daily to reach a customer base of 10 crore within five years. Having surpassed 7,000 stores, the omni-channel network seeks to enhance its neighbourhood presence and ensure widespread access to quality medicines. The company also reported its loyalty program, Apollo Circle, has crossed 10 million members.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8JLC52k
via IFTTT

Read More

Generic HIV drug rollout to take a hit on trial push

India's decision to reject a waiver for local clinical trials of a new HIV drug, lenacapavir, is causing concern. Public health experts warn this will delay access to the affordable generic version for millions in India and other low-income nations. Drug maker Hetero Labs sought the waiver to speed up the launch of the treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BDUcR9e
via IFTTT

Read More

Glenmark's Monroe facility classified as voluntary action indicated by USFDA

Glenmark Pharmaceuticals has received a positive report from the US health regulator. The company's manufacturing facility in Monroe, North Carolina, has been classified as Voluntary Action Indicated. This development means the facility can now restart commercial manufacturing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NTzZfPs
via IFTTT

Read More

Biocon's Bengaluru drug manufacturing facility gets 'Voluntary Action Indicated' classification

Biocon Biologics' drug substance facility in Bengaluru has been classified as Voluntary Action Indicated (VAI) by the USFDA. This classification means that while some objectionable conditions were found during the inspection, the agency is not pursuing regulatory action.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mD6zjSv
via IFTTT

Read More

Kauvery Hospitals' promoters look to buy back 5% stake from Lightrock

Kauvery Hospitals' leadership is engaged in discussions to repurchase shares from the investor Lightrock, with the valuation of the healthcare chain set at ₹5,000 crore. Anticipating a public offering in the next two years, the group is poised to ramp up its bed capacity significantly. The primary goal for the promoters is to reclaim a stronger stake in their enterprise.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RuNktyQ
via IFTTT

Read More

Lord’s Mark Industries acquires 85% stake in Renalyx to scale indigenous dialysis technology

Lord's Mark Industries has acquired an 85% stake in Renalyx Health Systems, a Bengaluru-based med-tech firm known for its AI-powered smart hemodialysis machine. This strategic move aims to bolster Lord's Mark's presence in advanced medical technologies, particularly for chronic kidney disease. Renalyx will spearhead R&D for kidney and liver devices, enhancing renal care accessibility across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jNZkagl
via IFTTT

Read More

China holds all the cards in global pharmaceuticals despite India’s bid to reshuffle the deck

China's dominance over raw materials for medicines presents a significant supply-chain vulnerability for the US. A US commission urges Congress to require pharmaceutical firms to report supply chain origins and encourage diversification away from China, highlighting the risks of over-reliance on a geopolitical rival.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/K5BSoNt
via IFTTT

Read More

Sterling Biotech case: GoI to examine impact of Supreme Court judgment

The government is reviewing the Supreme Court's Sterling Biotech judgment, which dropped criminal charges against promoters in exchange for a ₹5,100 crore payment. While not a precedent, the ruling raises concerns for lenders and could impact similar fraud cases, potentially encouraging other offenders to seek settlements.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/InojfUu
via IFTTT

Read More

Baby Memorial Hospital front-runner for Star Hospitals, Fortis also in fray

Baby Memorial Hospital, backed by KKR, is reportedly the front-runner to acquire Star Hospitals for ₹2,500-2,700 crore. Fortis Healthcare is also in contention for the Hyderabad-based hospital group. Star Hospitals, promoted by cardiologist Gopichand Mannam, has two facilities in Hyderabad and annual revenues of ₹500-600 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TMkXsQ6
via IFTTT

Read More

Glenmark launches fixed-dose triple therapy for COPD

Glenmark Pharmaceuticals has launched a groundbreaking nebulised triple therapy for COPD. This single, easy-to-use treatment combines three medicines to improve lung function and symptom control. It offers a new standard of care, especially for patients who find inhalers difficult. The therapy showed rapid improvement in lung function and breathlessness in a clinical study.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UGXfCxT
via IFTTT

Read More

US FDA approves Novartis' gene therapy for rare muscle disorder

The US FDA has approved Novartis' new gene therapy, Itvisma, which is for patients aged two and above with spinal muscular atrophy. Itvisma offers a new option for a broader patient group. The therapy aims to replace a faulty gene crucial for muscle function.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WXvlp1M
via IFTTT

Read More

NPPA extends price cap on knee implants by a year

India's drug pricing regulator has extended the price cap on knee implants. This decision will continue to benefit patients by keeping costs down. The National Pharmaceutical Pricing Authority decided not to revise the prices for another year. Manufacturers had argued for a price increase, citing research and development needs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HrkSoLW
via IFTTT

Read More

BlackRock exiting Rs 210 crore investment in People Tree Hospitals

People Tree Hospitals is facilitating an exit for BlackRock. BlackRock invested Rs 210 crore earlier this year. This investment aided the hospital chain's expansion and super-speciality services. It marked BlackRock's first major healthcare investment in India. People Tree Hospitals operates several branches across Bengaluru and Karnataka. Founder Jothi Neeraja stated commitment to honoring investor trust.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MsNBnAa
via IFTTT

Read More

Corner Office Conversation: Nandini Piramal of Piramal Pharma & Arjun Juneja of Mankind Pharma

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Aojdn7U
via IFTTT

Read More

Biocon chief bats for dual-agency model to fast-track drug approvals

Biocon's Kiran Mazumdar-Shaw suggests a new drug approval system. The Indian Council of Medical Research would handle scientific reviews for new drugs and devices. The Central Drugs Standard Control Organisation would then grant final regulatory approval. This aims to speed up innovation and research in India's biotechnology sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bF3Gr5p
via IFTTT

Read More

Aurobindo Pharma incurring loss at China Plant; hopes to achieve break-even by Q4

Aurobindo Pharma's China facility is set to achieve break-even by the end of fiscal year 2026. The company anticipates significant growth driven by its Pen-G facility ramp-up and biosimilar portfolio commercialization. The US market will see contributions from the Dayton facility starting January. Aurobindo aims for a 20-21 percent margin target for FY26.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HV0z9u1
via IFTTT

Read More

India mulls floating global tenders for key patented drugs amid supply gaps

The government is examining a proposal to float global tenders for more than 65 patented and proprietary medicines — including obesity, cancer, cardiac and diabetes drugs — to supply central healthcare institutions such as the armed forces’ medical wing and the Employees’ State Insurance Corporation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KxmGa58
via IFTTT

Read More

Pharma Industry warns minimum import prices plan could raise drug prices, hurt MSMEs

Pharma experts have flagged concerns over the government’s plan to set minimum import prices (MIP) for key drug ingredients such as Penicillin-G, 6APA and amoxicillin. They warn this will raise manufacturing costs, increase medicine prices and hurt over 10,000 MSMEs, potentially causing major job losses.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UrBJILh
via IFTTT

Read More

Government’s scheme to promote research and innovation evokes a massive response: Official

A month after the Department of Pharmaceutical (DoP) invited applications for research and innovation projects under its Promotion of Research and Innovation in Pharma-MedTech Sector (PRIP) scheme, an initiative to transform the sector into a globally competitive, innovation-driven sector, 700 applications have been received by the department so far.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ag4y0pc
via IFTTT

Read More

Biocon in very unique position globally as a biosimilars leader: Kiran Mazumdar-Shaw

Biocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to accelerate growth in the biologics space. The company is uniquely positioned with interchangeable biosimilar insulins and aims to capitalize on the growing GLP-1 market, bolstered by its acquisition of Viatris' biosimilars business.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XtATbsf
via IFTTT

Read More

Quality issues: Regulator looks to tighten marketing & sale of drugs

India's drug regulator plans new rules for medicine marketers. Companies will need a license to sell and distribute drugs. This aims to improve drug quality and safety. The move will impact domestic and multinational firms. It is expected to help curb fake medicines. The regulator seeks to create a database of marketers for better oversight.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/64tJVoU
via IFTTT

Read More

Eli Lilly wants to be part of making a big dent in obesity and diabetes, says co's India head Winselow Tucker

Eli Lilly India chief Winselow Tucker said the company’s strategy of combining a strong product with ecosystem partnerships and patient education has helped drive early momentum for Mounjaro in India, where the dual-action diabetes and obesity drug has clocked ₹450 crore in sales within seven months. He said India has a large unmet need, with nearly 100 million people living with obesity and diabetes, and that tirzepatide’s dual GIP and GLP-1 mechanism has set it apart in both weight and glucose management.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vM7qKj1
via IFTTT

Read More

Ultra-processed foods displacing fresh meals worldwide, driving chronic disease burden: Lancet

Ultra-processed foods are increasingly displacing healthier options globally, contributing to chronic diseases. Researchers urge immediate public health action, emphasizing coordinated policies to curb UPF production, marketing, and consumption. This requires challenging corporate influence and advocating for sustainable food systems.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wrFt7Tm
via IFTTT

Read More

Novo Nordisk India prioritises patient outcomes; revenue growth follows naturally, says Shrotriya

Novo Nordisk India head Vikrant Shrotriya revealed a strategic 37% price cut for obesity drug Wegovy, aiming for wider accessibility. The company is preparing for semaglutide patent expiry next year by focusing on trust, quality, and education, mirroring its successful insulin strategy. Ozempic is slated for launch within three months, with pricing to be determined by market research.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZpOYeD7
via IFTTT

Read More

After cough syrup deaths, drug regulator moves to tighten rules on high-risk solvents; unlicensed village pharmacies also under scrutiny

India's drug regulator is taking action after children died from contaminated cough syrups. They are looking into how to check the quality of ingredients like propylene glycol. The regulator is also considering stopping unlicensed pharmacists from selling cough syrups in villages. Experts are being consulted on whether to replace propylene glycol in these medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6b8A5l3
via IFTTT

Read More

NCLT clears Sequent Scientific–Viyash Life Sciences merger worth ₹8,000 crore

Carlyle's portfolio companies, Sequent Scientific and Viyash Life Sciences, have received National Company Law Tribunal approval for their planned Rs 8,000 crore merger. This strategic combination aims to leverage back-end synergies between Sequent's animal health business and Viyash's human health drug manufacturing operations. Hari Babu Bodepudi, Viyash's founder, will lead the combined entity as CEO.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/i0Y3AqC
via IFTTT

Read More

Patent expiry looms: Eli Lilly and Novo Nordisk strategise to defend their top obesity drugs in India

Eli Lilly and Novo Nordisk leaders share their India strategies for weight-loss drugs. They focus on pricing, market expansion, and countering generics after semaglutide's patent ends. Both companies aim to increase patient access to their innovative therapies. They are working with partners to reach more people across India. This ensures their medicines benefit a wider population.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gjzOyd6
via IFTTT

Read More

Import price floor on cards for critical pharma inputs

India is setting a minimum import price for essential drug ingredients. This move aims to shield local manufacturers from cheap imports, particularly from China. The government is expanding this policy to include more raw materials. This initiative supports India's goal of becoming self-reliant in pharmaceutical production. The new rules will soon be announced.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LpjBwfM
via IFTTT

Read More

Deep Diamond India to enter preventive healthcare segment

The digital-health initiative, Deep Health India AI, is an intelligent, camera-based wellness platform that uses facial-scan technology to deliver real-time health insights, the company said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IbtOxFS
via IFTTT

Read More

Pfizer launches new medication for migraine treatment

In a significant breakthrough for migraine sufferers in India, Pfizer has launched Rimegepant ODT, an innovative oral tablet that dissolves on the tongue. This medication provides rapid pain relief lasting up to 48 hours without the need for water, helping individuals reclaim lost days due to debilitating headaches.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oPjyJ34
via IFTTT

Read More

AI tool in national disease surveillance helped issue over 5,000 alerts to health authorities: Data

Nearly 200 countries are legally bound by the International Health Regulations (IHR) to operate a national disease surveillance system. The IHR and World Health Organization work together in protecting global health security. News reports in print, electronic and online media are scanned by media scanning and verification tool under India's 'Integrated Disease Surveillance Programme' (IDSP) for unusual health events, which are then shared with authorities for further action, if deemed necessary.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dwfPhjO
via IFTTT

Read More

Wealth Whisperers: Meet wealth psychologists who help the ultra-rich deal with money-related stress

Wealthy individuals, even after achieving financial success, often grapple with profound emotional turmoil like panic, insomnia, and identity loss. A new breed of professionals, wealth psychologists, are emerging to address the emotional meaning of money, helping the affluent navigate issues of guilt, isolation, and purpose beyond material gain.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TF4NeJi
via IFTTT

Read More

Three-day pharma industry event from Nov 25 to host global pharma leaders, exhibitors, investors

India's pharmaceutical industry total market size is projected to reach $130 billion by 2030 and an impressive $450 billion by 2047, highlighting the country's growing role as a global pharmaceutical powerhouse.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/319b6s5
via IFTTT

Read More

Lupin launches generic injection in US with 180-day exclusivity

In an exciting development for mental health treatment, Lupin has introduced a generic version of a medication for schizophrenia and bipolar disorder in the US. This innovative product comes as an extended-release injectable suspension and is backed by a remarkable 180 days of exclusivity. This launch illustrates Lupin's commitment to advancing complex injectable solutions in a growing US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TxpG8tF
via IFTTT

Read More

Small pharma firms may face closure as regulator tightens quality checks

Many small drug makers face closure as regulators inspect facilities for quality standards. Thousands of plants may shut down if upgrades are not made. This could lead to drug shortages. Industry groups are seeking more time to comply. The government has set a deadline for these upgrades. Companies must submit plans for improvement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Pv6ZORL
via IFTTT

Read More

Biocon considers merging Biocon Biologics in $4.5 billion deal; IPO and share swap options under review

Biocon is exploring merging its biosimilars arm, Biocon Biologics, with itself, potentially valuing the unit at $4.5 billion. The company is in advanced talks with minority investors for a share swap, considering various value creation options including an IPO or merger. This move aims to address acquisition-related debt and unlock shareholder value.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rdbjDKk
via IFTTT

Read More

Eli Lilly drops CVS drug plan for staff after Novo obesity deal: Report

Eli Lilly is switching its employee drug benefit plan from CVS Health to Rightway, a move reportedly linked to CVS's decision to stop covering Lilly's weight-loss drug Zepbound in favor of Novo Nordisk's Wegovy. Lilly stated the change was due to Rightway offering competitive fees and services aligned with employee interests.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8pKIOvw
via IFTTT

Read More

NTPC inks two pacts in Assam; to build burn ICU at KMCH, support TB patients

In a statement, the country's largest power producer said that it will construct a six-bed Intensive Care Unit (ICU) in the burn unit at Kokrajhar Medical College and Hospital (KMCH). The other project is nutritional support for 200 TB patients under the Pradhan Mantri TB Mukt Bharat Abhiyan in the district.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/173vOC2
via IFTTT

Read More

Lupin unit commissions oncology block at Vizag plant to expand CDMO biz

Drug firm Lupin has commissioned a new oncology block at its Vizag manufacturing plant. This dedicated unit will boost contract development and manufacturing services for high-potent active pharmaceutical ingredients. The facility supports clients throughout the oncology drug development lifecycle. It integrates process development and quality control labs for efficient operations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TbUCeEN
via IFTTT

Read More

Emcure Pharma Q2 profit rises 25%, revenue up 13% on broad-based growth

Pune-based Emcure Pharmaceuticals reported a 13.4% year-on-year rise in consolidated revenue to ₹2,270 crore in the September quarter, supported by double-digit growth in both domestic and international markets. Net profit increased 24.7% YoY to ₹251 crore, while EBITDA rose 15.2% to ₹439 crore, with a margin of 19.3%, the company said on Tuesday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uUoaJhO
via IFTTT

Read More

Novo, Emcure to launch weight-loss drug under new brand in India

In June, Novo Nordisk launched Wegovy (semaglutide) injections in five dosing strengths (0.25, 0.5, 1, 1.7 and 2.4 mg). However, the company has not yet disclosed pricing details for Poviztra. Wegovy is currently priced between ₹17,345 and ₹26,050 across dosages in India. It is prescribed for long-term chronic weight management and reduction in risk of major adverse cardiovascular events (MACE).

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TrXuex9
via IFTTT

Read More

Novo Nordisk ties up with Emcure to expand reach of weight-loss drug semaglutide in India

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide under the brand name Poviztra in India. This collaboration aims to expand access to the drug by leveraging Emcure's extensive distribution network and field force, addressing a significant need for wider reach beyond current accessibility.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bcV0lYA
via IFTTT

Read More

Novo Nordisk, Emcure to launch weight-loss drug under new brand in India

Novo Nordisk has partnered with Emcure Pharmaceuticals to bring Poviztra, their latest weight-loss medication, to the Indian market. This collaboration builds on Novo Nordisk's prior success with Wegovy and follows Eli Lilly's competition in this space. After the announcement, Emcure Pharma's stock experienced a notable uptick, signaling investor confidence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/W6fIDRJ
via IFTTT

Read More

Cyber fraud: Dr Reddy's Laboratories loses Rs 2.16 cr after fraudsters hack email communication

Bengaluru police are investigating a Rs 2.16 crore cyber fraud where hackers infiltrated email communications between Group Pharmaceuticals and Dr Reddy's Laboratories. The fraudsters impersonated Group Pharmaceuticals officials, diverting the payment to a fraudulent account in Gujarat. The primary account has been frozen, and efforts are underway to recover the funds.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PhZ6Ufs
via IFTTT

Read More

Apollo’s Suneeta Reddy and Dr Preetha Reddy on the Next 10 Years of Healthcare

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HEXR6dn
via IFTTT

Read More

Centre asks states to take steps to encourage organ, tissue donation from road accident victims

In India, the challenge of organ shortages looms large. The government is calling on states to amplify efforts in organ donation. Vital steps include training first responders and enhancing hospital trauma centers for effective organ recovery. This initiative specifically targets increasing the number of organ donors from tragic road accident cases.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2uCrJ7Q
via IFTTT

Read More

Venus Remedies gets new market authorisations for drugs in Vietnam

Pharma major Venus Remedies has received new marketing authorisations in Vietnam for its drugs Methotrexate, Cefuroxime, and Irinotecan. These approvals expand the company's presence in South Asia's growing pharmaceutical market. This marks 29 active product approvals for Venus Remedies in Vietnam alone. The company is committed to increasing access to critical care therapies in emerging markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x7skF8H
via IFTTT

Read More

Metsera accepts Pfizer's $10 billion bid in ongoing M&A battle

Metsera has accepted Pfizer's $10 billion acquisition offer. This ends a bidding war with rival Novo Nordisk. Pfizer will pay $86.25 per share. Metsera's board recommended shareholders approve the deal. Pfizer aims to strengthen its position in the growing weight-loss drug market. The merger is expected to close soon after Metsera's shareholder meeting.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ujIGeUB
via IFTTT

Read More

Drug regulator for strict compliance with new Schedule M

The state drug regulators have been asked to submit monthly reports to the Central Drugs Standard Control Organisation on the inspections and observations made and the action taken pursuant to such inspections. "This may be treated as top priority and compliance is required to be ensured strictly," the regulator said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UfdV5a6
via IFTTT

Read More

Alembic Pharmaceuticals gets USFDA nod for generic blood cancer treatment drug

Alembic Pharmaceuticals has secured final approval from the USFDA for its generic Dasatinib tablets. These tablets are used to treat certain blood cancers in adults and children. The approval covers multiple strengths of the drug. Dasatinib is a vital medication for patients with Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2v3le85
via IFTTT

Read More

Obesity drug Mounjaro becomes India's top-selling drug by value in October

Eli Lilly's Mounjaro drug has become India's top seller for October as sales reached one billion rupees. This anti-obesity medication helps control blood sugar and slows digestion. Demand for such drugs is increasing in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MFQHWda
via IFTTT

Read More

'Opaque pricing cripples Ayushman drug coverage'

The Ayushman Bharat program successfully delivers hospital care, but it falters when tackling the high costs associated with medications for chronic and rare conditions. Patients frequently have to pay out of pocket for these essential drugs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nUkz5Dv
via IFTTT

Read More

Apollo Hospitals eyes Q4 FY26 listing for HealthCo amid major restructuring

Apollo Hospitals plans to list its Apollo HealthCo arm by the fourth quarter of FY27, following a multi-layered restructuring. The hospital chain is also set to add approximately 3,650 operating beds over the next five years with an investment of Rs 8,300 crore, funded by internal accruals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aR9TDjW
via IFTTT

Read More

Bayer gets nod to market Kerendia for heart failure treatment

Bayer has secured approval in India for its therapy Kerendia to treat heart failure. This drug, finerenone, is already used for chronic kidney disease linked to type 2 diabetes. The expanded use targets heart failure types that have lacked effective treatments. Finerenone now addresses major health issues in India, including cardiovascular and kidney diseases.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/r75jNz8
via IFTTT

Read More

Sun Pharma’s US innovative drug sales surpass generics for the first time

Sun Pharma's U.S. innovative medicine sales have surpassed generics for the first time, driven by key products like Ilumya and Cequa. The launch of Leqselvi for alopecia has been well-received, with further growth anticipated from upcoming launches like Unloxcyt. This marks a significant shift in the company's revenue streams.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/U6reqMC
via IFTTT

Read More

Zydus gets USFDA's orphan drug designation for beta-thalassemia product

Zydus Lifesciences announced a significant development for beta-thalassemia patients. The US Food and Drug Administration has granted Orphan Drug Designation to Desidustat. This novel product aims to treat the rare blood disorder. The designation supports the development of medicines for diseases affecting fewer than 2 lakh people in the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ixsU2Vp
via IFTTT

Read More

Sun Pharma's US innovative drug sales surpass generics for first time

Sun Pharma is open to expanding its US manufacturing capabilities in response to the Trump administration's 100% tariff on medicines. The company is evaluating its current footprint and considering localization options, though the tariff's impact on its product portfolio remains uncertain. Sun Pharma also confirmed upcoming launches and R&D investments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7qIJbws
via IFTTT

Read More

Novelis says September fire at New York plant to hit FY26 cash flow up to $550-650 mn

Novelis anticipates a significant financial hit from a September fire at its New York plant. The company expects free cash flow to decrease by $550-650 million this financial year. Adjusted earnings before interest, tax, depreciation and amortisation will also be impacted. Restoration efforts are underway, with the Hot Mill expected to restart by end-December 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ios8Z9F
via IFTTT

Read More

Novelis expects cash flow impact of up to $650 mn from Oswego fire

Novelis anticipates a $550-$650 million negative impact on free cash flows this fiscal due to a September fire at its Oswego unit. The company expects to restart the hot mill in December, with insurance expected to cover 70-80% of property damage and business interruption losses.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iswVXtx
via IFTTT

Read More

Knee implant ceiling rates to be reviewed

Next week, the National Pharmaceutical Pricing Authority (NPPA) of India will delve into the pricing caps for knee implants, a move that previously helped slash costs for patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OrTcBNL
via IFTTT

Read More

Glenmark to launch generic drug to treat metabolic acidosis in US

Glenmark Pharmaceuticals is set to launch an 8.4 per cent Sodium Bicarbonate Injection in the United States. This generic medication treats high acid levels in the body. The company expects to begin distribution this month. The drug is therapeutically equivalent to Abbott Laboratories' product. This move follows significant annual sales for the medication in the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/niSgEa2
via IFTTT

Read More

Novo sharpens India focus with bigger bets on niche hospitals

Novo Holdings is boosting its investments in India. The company is looking at single-specialty hospitals and contract drugmakers. This move targets high-growth healthcare segments. Novo Holdings is already in talks with several Indian companies. Their investment size in India has grown significantly. They are focused on specialized healthcare and complex drug manufacturing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/d7owOcB
via IFTTT

Read More

Cipla to fully acquire Inzpera Healthscience

Drug maker Cipla has acquired Inzpera Healthscience for approximately Rs 111 crore. This strategic move combines Inzpera's paediatric products with Cipla's distribution strength. The deal aims to boost growth and scalability in the pharmaceutical and wellness sector. Inzpera, founded in 2016, focuses on differentiated paediatric offerings. The acquisition marks a significant step for Cipla in expanding its market presence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ePsfdvb
via IFTTT

Read More

AIMS hospital founder looks to buy back PE investors' 49% stake

In a bold move to regain control, Narendra Pandey, the visionary behind the Asian Institute of Medical Sciences, is negotiating to repurchase a 49% share from private equity players. He aims to secure around ₹500 crore for this venture as the hospital’s current valuation hovers between ₹1,000-₹1,200 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RJLiBpe
via IFTTT

Read More

AI helping doctors spend more time with patients, cut down on paperwork: Stanford Medicine’s Priya Singh

In an interview with The Economic Times, Priya Singh, Chief Strategy Officer and Senior Associate Dean at Stanford Medicine, talks about how Stanford is building the next generation of healthcare leaders through executive education and artificial intelligence. She explains that the programmes—targeted at senior and mid-level healthcare professionals—focus on leadership and innovation rather than serving as pathways to U.S. jobs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MCt83oO
via IFTTT

Read More

Narayana Health buys UK's Practice Plus Hospitals

Bengaluru's Narayana Health is making waves in the UK healthcare landscape with its acquisition of Practice Plus Group Hospitals, which manages 12 facilities. This strategic move is all about delivering affordable healthcare options to a broader audience.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uJTX7bp
via IFTTT

Read More

Narayana Health acquires UK’s Practice Plus Group Hospitals in Rs 2,200 crore deal

Narayana Hrudayalaya Ltd has acquired UK's Practice Plus Group Hospitals for approximately Rs 2,200 crore. This strategic move marks Narayana Health's entry into the UK healthcare market. The acquisition includes seven hospitals and several other facilities. Dr Devi Shetty stated the deal aims to make private healthcare more accessible and affordable.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mZigRxT
via IFTTT

Read More

US biosimilar norms to keep local drug cos in good health

With the new regulations set by the US FDA, the pathway to creating biosimilars will be both faster and more cost-effective. This development is a game changer for Indian firms like Biocon and Dr Reddy's Laboratories, allowing them to provide more economical medicines to patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FT7B2hj
via IFTTT

Read More

Made in India new generation heart stent receives major global recognition

An Indian-made heart stent, Supraflex Cruz, has demonstrated a lower failure rate in high-risk patients compared to a US-made market leader. The TUXEDO-2 trial, conducted in India, showed the Indian stent to be non-inferior and resulted in significantly lower Target Lesion Failures, including cardiac death and heart attacks.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aiTWQR7
via IFTTT

Read More

Cipla plans 4 major respiratory launches by 2026 after beating Q2 estimates with highest-ever quarterly revenue of Rs 7,500+ cr

Cipla Ltd reported a record second-quarter revenue exceeding Rs 7,500 crore, driven by strong demand for its respiratory drugs and a growing chronic portfolio. The company maintained its second position in India's chronic market and saw significant progress in its U.S. respiratory and biosimilar segments, with four major respiratory assets slated for launch by 2026.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vJO7TED
via IFTTT

Read More

Zero GST on health insurance plans sparks 38% surge in demand: Report

Health insurance demand has surged by 38 percent following the removal of GST. Individuals are now opting for higher coverage amounts, with the average sum insured increasing significantly. This trend is observed across various age groups and even in smaller cities. The exemption makes health and life insurance more affordable, encouraging comprehensive protection against rising healthcare costs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PJdcy73
via IFTTT

Read More

Drug cos forging data for approval, mislabelling brands to be barred

In a bold move to combat deception in the pharmaceutical industry, the government is instituting strict penalties for drugmakers caught submitting forged or misleading documents during the approval process. This initiative is a direct response to the tragic incidents of child fatalities linked to tainted cough syrups.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4ltOwLk
via IFTTT

Read More

Govt aligns packaging rules for medical devices, eases compliance burden

Attention healthcare providers: New packaging regulations for medical devices have just come into effect! These amendments are designed to ensure that packaging aligns seamlessly with existing medical device standards. This simplification not only supports businesses by streamlining compliance but also enhances clarity for consumers making informed choices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Yko71jI
via IFTTT

Read More

Amway to invest $12 million in India to enhance physical presence

Amway plans a USD 12 million investment in India over the next three to five years. This will establish new stores nationwide, aiming to boost Amway's presence. The company also intends to increase exports from India. Amway sees India as a significant growth market with strong potential for its health and wellness products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TCHlwZn
via IFTTT

Read More

Indian pharma & healthcare sector saw $3.5 bn deals in Q3 2025: Grant Thornton Bharat

The Indian pharmaceutical and healthcare sector saw robust deal activity in Q3, with 72 transactions totaling USD 3.5 billion. This surge, driven by a sharp rebound in private deals and high-value acquisitions like Torrent Pharma's stake in JB Chemicals, reflects renewed investor confidence in the sector's growth potential and consolidation plays.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZAxQeoK
via IFTTT

Read More

Sanofi India appoints Deepak Arora as Managing Director

Sanofi India has appointed Deepak Arora as its new Managing Director. Arora will lead the company's strategic vision for India, aligning it with Sanofi's global strategy. He will focus on accelerating innovation and agility across the organization. Arora brings over 30 years of pharmaceutical and healthcare experience from various international markets. His appointment aims to enhance patient service throughout India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pb75vEl
via IFTTT

Read More

Dr Reddy’s gets nod to make generic semaglutide for weight loss

Dr Reddy's Laboratories is set to launch generic semaglutide, a popular weight loss drug. An expert committee has approved their proposal. The company plans to market the drug as soon as Novo Nordisk's patent expires early next year. This move aims to tap into a growing market for obesity and diabetes management. Dr Reddy's is preparing for a competitive launch.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/E4PLRBv
via IFTTT

Read More

Lupin launches generic drug to treat urea cycle disorders in US

Drug firm Lupin has launched a generic medication in the US. This new drug treats urea cycle disorders. It is an authorized generic version of Ravicti oral liquid. The medication helps patients manage the disorder. This is for those who cannot be managed by diet alone. Lupin's shares saw a slight dip on the BSE.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/StLxhry
via IFTTT

Read More

Time has never been better for Pharma breakthroughs than today: Bayer executive Stefan Oelrich

Bayer, the renowned pharmaceutical powerhouse from Germany, is implementing a tiered pricing strategy on a global scale to make medications more accessible. The CEO emphasizes the necessity of earning returns to justify research investments. As innovation ecosystems shift, particularly towards regions like China, Bayer is proactively adapting.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/foMhiNY
via IFTTT

Read More

Eli Lilly allows Cipla to sell weight loss drug under new brand in India

Eli Lilly and Cipla have joined forces. Cipla will now market Lilly's popular weight-loss drug in India. The medication will be sold under the brand name Yurpeak. This drug helps manage diabetes and obesity. It is administered as a once-weekly injection. Yurpeak will be available in multiple dose strengths.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IX3GM0D
via IFTTT

Read More

Biocon gets Health Canada nod for biosimilars Yesintek, Yesintek IV

Biocon Biologics has made strides in the healthcare sector by obtaining Health Canada’s approval for Yesintek and Yesintek IV, its latest autoimmune treatment options. These biosimilars to Stelara have received official clearance on October 17, heralding a new era of affordable treatment in Canada.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/z9nY6Mk
via IFTTT

Read More

Trump eyes fresh tariff probe focused on foreign drug prices

President Trump is initiating a new investigation into drug prices, aiming to compel foreign nations to pay the same as Americans for their medicines. This probe, under Section 301 of the Trade Act, could lead to tariffs or other trade actions against countries with lower drug costs, potentially escalating global trade tensions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/diflSr2
via IFTTT

Read More

Regulator to digitally monitor supply chain of cough syrups

In a groundbreaking effort to enhance public health safety, India's drug regulatory authority has unveiled a digital tracking system for cough syrup supplies. This initiative comes in response to alarming cases of harmful cough syrups surfacing in the market. The revamped Online National Drugs Licensing System now requires pharmaceutical manufacturers of solvents to register and obtain licenses through this portal.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gkDGzXA
via IFTTT

Read More

COVID-19 vaccines may help some cancer patients fight tumors

New research suggests COVID-19 mRNA vaccines could help cancer patients. Those with advanced lung or skin cancer who received Pfizer or Moderna shots lived longer while on immunotherapy. The mRNA technology appears to enhance the immune system's ability to fight tumors. This finding offers a potential new approach for cancer treatment, with further studies planned.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1ZvlNyb
via IFTTT

Read More

CCI clears Torrent Pharma's proposal to buy stake in JB Chemicals

India's competition regulator CCI has approved Torrent Pharmaceuticals' acquisition of a stake in JB Chemicals and Pharmaceuticals. This deal, valued at Rs 19,500 crore, will make Torrent Pharmaceuticals the second most valued pharma company in India. The approval comes with voluntary modifications offered by both companies. This significant development marks a major consolidation in the Indian pharmaceutical sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pE0Q7tI
via IFTTT

Read More

Dr Reddy's Srikakulam unit classified as voluntary action indicated by USFDA

Dr Reddy's Laboratories has received a report from the US Food and Drug Administration. The report concerns its manufacturing facility in Srikakulam, Andhra Pradesh. The USFDA has classified the inspection outcome as Voluntary Action Indicated. This means the inspection is officially closed. The company received the Establishment Inspection Report on October 20, 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BPErcRQ
via IFTTT

Read More

Glenmark, Dr Reddy's recall products in US: USFDA

Indian drugmakers Glenmark and Dr Reddy's Laboratories are recalling products in the United States. Glenmark is recalling oral contraceptive medication due to failed impurities. Dr Reddy's Laboratories is recalling muscle relaxant medication due to out-of-specification results. These recalls are initiated by the US Food and Drug Administration. India has many USFDA-compliant plants outside the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BU49wPp
via IFTTT

Read More

India develops first indigenously discovered antibiotic "Nafithromycin" effective against resistant respiratory infections

India has proudly introduced Nafithromycin, its first homegrown antibiotic, tackling stubborn respiratory infections with groundbreaking efficacy. Coupled with a significant leap in gene therapy for Haemophilia, these innovations underscore India's commitment to self-sufficiency in the pharmaceutical arena. The country is now embracing a model that fosters collaboration with the private sector, setting the stage for international acclaim in biomedical research.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sxOXMFd
via IFTTT

Read More

Strides Founder raises Rs 1000 crore to refinance debt

Arun Kumar, founder of Strides Group and OneSource, has secured ₹1,000 crore by pledging shares. This move refinances existing loans, extending maturities and simplifying repayments. The transaction aims to consolidate smaller borrowings into larger, long-term facilities. It reflects a broader effort to clean up the promoter's balance sheet and shows a decline in pledged shares, indicating deleveraging.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eUxw2VP
via IFTTT

Read More

Prerna launches CANTEL™: A MicroRNA-based blood test for breast cancer screening

PrecisionRNA Biotech from Hyderabad has launched Cantel, a new microRNA blood test for breast cancer screening. This test offers a simple and accurate alternative to traditional methods. It aims to improve early detection rates in India. Cantel is designed for women aged 30 and above. The company is seeking investors for nationwide expansion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FuEgW63
via IFTTT

Read More

Indian firms explore localisation of pharma production in Russia

The Russian market is attracting growing interest from Indian pharmaceutical companies exploring opportunities to establish production facilities across various regions of the country. This was announced by Moscow Government Minister and Head of the Department for External Economic and International Relations, Sergey Cheremin, during the " Russia-India. Mutual Efficiency" forum.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/amfci7u
via IFTTT

Read More

US Senator raises alarm over poor-quality drug imports from India and China, seeks tougher FDA inspections

In a letter to FDA Commissioner Martin Makary, Banks said the agency must "do more to protect the US drug supply," warning that lax oversight could endanger American consumers. He pointed out that inspections of foreign drug plants have not yet returned to pre-pandemic levels, even as the number of manufacturers continues to grow.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xEIYczF
via IFTTT

Read More

India to force drugmakers to upgrade plants after fatal cough syrup crisis

India has denied drugmakers more time to upgrade manufacturing facilities. This decision follows the deaths of at least 24 children from contaminated cough syrup. The government mandated World Health Organization standards after similar incidents abroad. Despite pleas from smaller firms, officials are firm on the deadline.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jZH0vhU
via IFTTT

Read More

Alchem International moves Delhi HC against single-judge order on ‘Alchem’ trademark

Alchem International is challenging a court order that stops it from using its name. The order prevents Alchem from selling products with the name 'Alchem' due to similarity with Alkem Laboratories' trademark. A division bench is reviewing the case. The court previously found the names phonetically identical. Alkem has used its trademark since 1973. Alchem started using its mark later.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oKYmCbZ
via IFTTT

Read More

Heart blockages, tumors, fractures: Now, you can see what’s wrong inside your body in 3D at this Delhi govt hospital

Delhi-NCR's Vardhman Mahavir Medical College and Safdarjung Hospital has introduced a virtual clinical anatomy laboratory. Patients can now view detailed 3D models of their own bodies. This technology uses CT or MRI scans to create interactive visuals of organs, bones, and tissues. It helps patients understand their medical conditions and treatments better.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/imOeHXW
via IFTTT

Read More

Lords Mark Industries Ltd. secures US FDA Registration, reinforces India’s position in global healthcare manufacturing

Lords Mark Industries Ltd. has achieved a significant milestone with US FDA registration for its surgical consumables, orthopedic supports, and hygiene products. This recognition underscores the company's manufacturing excellence. It opens doors to international markets, boosting exports and India's global healthcare manufacturing standing. The approved portfolio covers a wide range of essential healthcare items.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3zsQDLj
via IFTTT

Read More

Under the scanner, yet generic cough syrups hit shelves

Worry spreads regarding the multitude of cough syrup brands circulating in India, with alarming revelations of toxic diethylene glycol detected in some, resulting in heartbreaking instances of child mortality. This situation sheds light on the questionable efficacy of regulatory measures, as many small-scale producers evade scrutiny.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kwLCu7p
via IFTTT

Read More

Centre plans new law for stricter quality checks and surveillance of drugs, medical devices, and cosmetics

India is creating a new law to improve drug quality and safety. This legislation will give more power to regulators for checking medicines, medical devices, and cosmetics. The aim is to prevent fake and substandard products. This move follows global concerns and recent incidents.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aYiSLR4
via IFTTT

Read More

Centre to bring law for strict quality checks, surveillance of drugs and cosmetics

India is creating a new law to improve drug quality and safety. This legislation will give more power to regulators for testing and monitoring medicines, medical devices, and cosmetics. The aim is to ensure stricter compliance and accountability. This move follows global concerns and recent incidents.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Fglp7bm
via IFTTT

Read More

Cloudnine Hospitals leads race to acquire Apollo Cradle

Cloudnine Hospitals is stepping into a pivotal role in the maternity and pediatric care sphere, as it engages in advanced discussions to acquire Apollo Cradle and Children's Hospital at a valuation of around ₹1,500 crore. Having signed an exclusivity pact, Cloudnine has kicked off due diligence procedures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NId1qZM
via IFTTT

Read More

Roche moves SC against Natco’s launch of generic Risdiplam in India

F. Hoffmann-La Roche AG has approached the Supreme Court. This follows a Delhi High Court decision permitting Natco Pharma to introduce a generic version of Risdiplam. Risdiplam treats spinal muscular atrophy. The High Court rejected Roche's plea to halt Natco's manufacturing. Natco plans to sell the drug at a significantly lower price.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7rRmOF1
via IFTTT

Read More

India accuses Balaji Amines of making pharma-grade chemical without a drug-making licence

Balaji Amines faces accusations from Indian authorities for producing pharma-grade propylene glycol without a necessary drug manufacturing license. This comes after some batches were found to be substandard. The company states it only manufactured technical and food-grade PG for non-pharma clients. Investigations are ongoing, and the company's stock has seen a decline.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jFZ4eQd
via IFTTT

Read More

Aurobindo Pharma promoters raise Rs 2k cr to fund realty, other asset buys

The transaction is split into two parts. The Rs 650 crore Series 1 comes with a 24-month tenor and a two-year put and call option, and Rs 1,450 crore, which will be Series 2 with a four-year tenor. Series 1 will carry a coupon of 11.75%, while Series 2 is likely to be priced at 15.5%.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9qK7MPH
via IFTTT

Read More

WHO warns of contaminated India cough syrups linked to 17 child deaths

The World Health Organization has issued a health advisory regarding three contaminated cough syrups from India. Specific batches of COLDRIF, Respifresh TR, and ReLife are identified. These products pose severe health risks. India's Central Drugs Standard Control Organization reported that 17 children under five died after consuming these syrups. Authorities confirm no contaminated medicines were exported from India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3HltM0L
via IFTTT

Read More

Cough Syrup deaths: Sresan Pharmaceuticals' license cancelled, company shut down

Tamil Nadu has cancelled the manufacturing license of Sresan Pharmaceutical, maker of Coldrif cough syrup, after it was linked to at least 22 deaths in Madhya Pradesh due to toxic contaminants. The state ordered comprehensive inspections of all pharmaceutical units following the incident and the arrest of the company owner.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PO1INFa
via IFTTT

Read More

ED raids seven Chennai sites linked to Sreesan Pharma over Coldrif cough syrup deaths

The Enforcement Directorate (ED) conducted searches at seven locations in Chennai concerning the Coldrif cough syrup case. These raids, under the PMLA, are linked to Sreesan Pharma, the manufacturer of the banned syrup. The cough syrup has been linked to the deaths of approximately 22 children, primarily in Madhya Pradesh and Rajasthan.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KQfagzI
via IFTTT

Read More

DRL, Zydus recall drugs in US over manufacturing issues: USFDA

Dr Reddy's Laboratories and Zydus Lifesciences are recalling products in the US due to manufacturing issues. Dr Reddy's is recalling muscle relaxant injections over stability testing failures, while Zydus Lifesciences is recalling antiviral medication for failing impurity specifications. Both recalls are classified as Class II by the USFDA.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u9rhU6i
via IFTTT

Read More

Survey finds 90% Indians willing to pay more for certified healthcare

A Ficci and EY-Parthenon report reveals that 83% of Indian patients desire accessible healthcare information, with nearly 90% willing to pay more for certified quality. Despite India's healthcare efficiency, a national framework for clear quality standards is needed to empower informed patient choices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SgXm82Z
via IFTTT

Read More

Breast cancer cases on rise; junk food, lack of exercise contributing factors: Doctors

Breast cancer is a growing concern in India, projected to reach two lakh cases annually by 2030. Experts highlight lifestyle factors like lack of exercise, obesity, and westernized diets as key contributors. Genetic predispositions also play a role, necessitating increased genetic testing and early screening for high-risk individuals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TrWEhVU
via IFTTT

Read More

Natco Pharma to acquire significant stake in S African firm Adcock Ingram

Indian pharmaceutical company Natco Pharma is set to acquire significant stakes in South Africa's Adcock Ingram, a 135-year-old firm, in a R4.2 billion deal. This acquisition will make Adcock Ingram a privately-held entity, co-owned by Natco and Bidvest, with Adcock Ingram delisting from the JSE post-completion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uCvon8O
via IFTTT

Read More

Max Healthcare plans over ₹5,000 crore expansion, eyes pan-India presence: MD Abhay Soi

Max Healthcare has surpassed ₹1 lakh crore in market capitalization, becoming India's most valued healthcare company. The company plans a significant capex of over ₹5,000 crore for expansion, aiming to increase bed capacity substantially and extend its reach into tier-2 and tier-3 cities across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8rt5jeA
via IFTTT

Read More

Panacea Biotec bags Rs 127 crore order for oral polio vaccines

Panacea Biotec has secured a significant deal to supply bivalent oral polio vaccines valued at Rs 127.2 crore to the Central Medical Services Society. This crucial supply, confirmed via a Letter of Acceptance, will be delivered in multiple phases over 90 to 480 days, bolstering India's ongoing polio eradication efforts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oU9hItu
via IFTTT

Read More

Trump & Co said to have shelved generic drug tariffs, Indian pharma stocks get booster dose

The Trump White House has halted plans for tariffs on generic drug imports, a decision welcomed by Indian pharmaceutical companies that supply nearly half of US generic prescriptions. This move reassures millions of Americans relying on affordable imported medications for various health conditions, averting potential price hikes and shortages.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ae6w8Wk
via IFTTT

Read More

MP cough syrup deaths: Maharashtra FDA orders inspection of liquid oral formulations

Following the deaths of 20 children in Madhya Pradesh due to a contaminated cough syrup, the Maharashtra FDA has initiated a special drive. This includes inspecting manufacturers and testing liquid oral formulations from hospitals and distributors to ensure quality and prevent similar incidents.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cJTtEmL
via IFTTT

Read More

Drug regulatory body steps up heat on state units amid cough syrup lapses

India's drug regulator has directed state authorities to enforce strict testing of all raw materials used in medicines. This action follows the tragic deaths of children due to contaminated cough syrups. Investigations revealed manufacturers were not testing excipients, leading to the use of industrial-grade materials unfit for human consumption.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mwY1vCO
via IFTTT

Read More

Eli Lilly's obesity drug Mounjaro's India sales hit a sweet spot within six months of launch

Lilly's Mounjaro has rapidly become the second-highest selling drug in India's pharmaceutical market, achieving ₹233 crore in sales within six months of its March launch. The weight-loss and diabetes medication posted ₹80 crore in September sales, surpassing popular brands and attributed to its superior efficacy and first-mover advantage over competitors.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VGHjYOt
via IFTTT

Read More

Sresan Pharma, maker of Coldrif, broke multiple rules: Officials

Sresan Pharma, the manufacturer of Coldrif cough syrup linked to at least 16 child deaths, allegedly ignored numerous quality standards. A central inspection revealed a "shoddy and neglected state" at their Tamil Nadu facility, with significant violations in raw material testing and batch release.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tYyUbXI
via IFTTT

Read More

The first 90 days: A doctor’s checklist for people newly diagnosed with type 2 diabetes

The first 90 days after a type 2 diabetes diagnosis are crucial for managing the condition and reducing heart disease risks. Experts emphasize understanding the body's response to high blood sugar, adopting healthy lifestyle foundations like smart eating and regular exercise, and seeking support to lay the groundwork for long-term health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u2sLQ5r
via IFTTT

Read More

Eli Lilly to invest $1 billion in India, expand manufacturing and introduce oral weight-loss drug

Eli Lilly is significantly expanding its Indian operations with over $1 billion in contract manufacturing investments and plans for a global capability center. The US pharma giant is positioning India as a key hub, preparing to introduce an oral version of its experimental weight loss drug orforglipron and a new manufacturing hub in Hyderabad.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zgTGPxw
via IFTTT

Read More

"Classical example of legal illiteracy": IMA on arrest of doctor in child deaths from contaminated cough syrup

The Indian Medical Association has condemned the arrest of a pediatrician in Madhya Pradesh following child deaths from contaminated cough syrup, calling it "legal illiteracy" by police. The IMA demands action against actual culprits and compensation for affected families, emphasizing regulatory failures and the spurious nature of the drug.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kPIKN2R
via IFTTT

Read More

Kerala bars all medicines for children under 12 without prescription

Kerala's Health Department mandated doctor prescriptions for all medicines given to children under 12, citing cough syrup concerns. An expert panel will study cough medicine use to formulate new guidelines. This follows reports of child deaths outside Kerala linked to toxic cough syrups, prompting awareness campaigns and suspension of problematic batches.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NrbwHzf
via IFTTT

Read More

Nanavati Max Hospital inks pact with Namangan Viloyat Republic Hospital in Uzbekistan

Mumbai's Nanavati Max Super Speciality Hospital has partnered with Uzbekistan's Namangan Viloyat Republic Hospital to enhance medical services. This collaboration facilitates knowledge exchange and clinician training in key specialties like multi-organ transplantation, while also providing advanced treatment for Uzbek patients in India. The agreement aims to establish transplant programs and streamline patient care pathways.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Hz69rVK
via IFTTT

Read More

Eli Lilly to invest over $1 billion in India to expand manufacturing capacity

Eli Lilly will invest over $1 billion in India to boost manufacturing and supply through local drugmakers, increasing the availability of key drugs like Mounjaro. This strategic move leverages India's skilled workforce and includes a new Hyderabad facility to oversee contract manufacturing, despite global shifts towards US production.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xzfFbtB
via IFTTT

Read More

Cough syrup issue: Health ministry directs rational use of medication

Union health secretary convened a meeting with states to address drug quality after multiple child deaths linked to contaminated cough syrups like Coldrif, found with DEG/EG. States were directed on rational use, while DGHS advised against prescribing such medicines for children under two, emphasizing careful evaluation for older kids. Probes are underway, and some states have banned the syrups.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fpu3oe4
via IFTTT

Read More

NSE to build Rs 380-crore facility for cancer treatment at Tata Memorial Centre

NSE will build a 380 crore rupee cancer treatment facility at Tata Memorial Hospital. This 11-storey block and bone marrow transplant centre will be in Navi Mumbai. It will serve 1.3 lakh outpatients and conduct over 600 BMTs annually. The facility will have 60 beds. Operations are expected to begin by July 2027.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/E3MQqC6
via IFTTT

Read More

India's TB fight gets a boost: New Made-in-India diagnostic tests cut cost & time

India's ICMR has validated two new indigenous TB diagnostic tools from Huwel Lifesciences. The Quantiplus MTB FAST kit offers cheaper, open-system RT-PCR testing on existing machines, while UniAMP MTB uses non-invasive tongue swabs for patient-friendly diagnosis. These innovations promise faster, more accessible, and affordable TB detection, boosting India's elimination efforts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HYprjS0
via IFTTT

Read More

Torrent Pharma gets demand notices totalling Rs 6.63 cr from NPPA

Torrent Pharmaceuticals reported receiving demand notices from the NPPA. The notices total over Rs 6.63 crore. They allege overcharging for five drugs between January 2016 and November 2018. The company stated these notices were received on October 3, 2025. Torrent Pharmaceuticals expects no material financial impact from this development.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yrTJDqE
via IFTTT

Read More